User:Stellatarum/Emergent BioSolutions

Emergent BioSolutions (nyse: EBS) is a multinational biopharmaceutical company headquartered in Rockville, Maryland. Emergent develops vaccines and therapeutics targeting infectious diseases, oncology and autoimmune disorders. The company was founded as BioPort Corporation in 1998 and became Emergent BioSolutions in 2004. Since the early 2000s, Emergent has expanded its product development, including research and development of products through joint ventures.

Overview
Emergent BioSolutions focuses on the development and manufacture of vaccines and therapeutics for the prevention or treatment of disease. Fuad El-Hibri is the chairman and CEO of Emergent BioSolutions and has led the company since it was founded as BioPort Inc. in 1998. The company's headquarters is in Rockville, Maryland.

History
In 1998, the BioPort Corporation was founded to acquire an anthrax vaccine manufacturing facility in Lansing, Michigan, and other assets of the Michigan Biologics Products Institute, formerly owned by the Michigan Department of Public Health. In addition to the Lansing facility, BioPort acquired the license to produce anthrax vaccine for the U.S. Department of Defense. After corporate restructuring in 2004, BioPort and its subsidiary Antex Biologics became wholly-owned subsidiaries of Emergent BioSolutions Inc. In November 2006, Emergent held its initial public offering (IPO) on the New York Stock Exchange.

Product development
In 2006 and 2007, Emergent had carried out development of medications and vaccines for the treatment of typhoid, hepatitis B and streptococcus, for which development is no longer being pursued. , Emergent's product development pipeline includes product candidates targeting infectious diseases, oncology and autoimmune disorders.

BioThrax (Anthrax Vaccine Adsorbed)
BioThrax (Anthrax Vaccine Adsorbed) is a vaccine licensed by the U.S. Food and Drug Administration. Following a study by scientists from the Centers for Disease Control and Prevention, on December 19, 2008, Emergent received final FDA licensing for use of BioThrax five doses for intramuscular injection. On February 11, 2009, the company announced that it had been granted a license to distribute BioThrax in India. Later in 2009, Emergent received approval from the FDA to extend the shelf life of its anthrax vaccine from three to four years. In 2011, BioThrax was approved for sale in Singapore by the Singapore Health Sciences Authority.

Acquisitions
Emergent has added to its product pipeline through the acquisition of other biotechnology and pharmaceutical companies, including Antex Biologics Inc., a pharmaceutical research and development company, in 2003, and Microscience Ltd. (based in the United Kingdom) in 2005. In August 2006, Emergent purchased Vivacs GmbH, a biotechnology company based in Munich, Germany. On March 6, 2008, Emergent completed the acquisition of a group of anthrax monoclonal antibodies from Avanir Pharmaceuticals. On May 5, 2008, Emergent acquired patents and processes of VaxGen, Inc., of Livermore, California, including VaxGen's anthrax vaccine program. Emergent acquired Trubion Pharmaceuticals Inc. in October 2010, providing Emergent with oncology and autoimmune disease treatment candidates. In 2011, it acquired the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy from TenX BioPharma, Inc.